Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Deutsche Boerse AG  >  Roche Holding Ltd.    RHO5   CH0012032048

ROCHE HOLDING LTD.

(RHO5)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Roche to Acquire Spark Therapeutics

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/25/2019 | 01:30am EDT

By Anthony Shevlin

Roche Holding said Monday that it entered a definitive merger agreement to acquire Philadelphia-based Spark Therapeutics.

The Swiss pharmaceutical company said it would acquire Spark for $114.50 per share and that the deal is expected to close in the second quarter.

Under the terms of the deal, Roche will file a tender offer to acquire all outstanding shares of Spark common stock, and Spark will file a recommendation statement containing the unanimous recommendation of the Spark board that its shareholders tender their shares to Roche.

Spark Therapeutics specializes in discovering, developing and delivering gene therapies. Its lead clinical asset is SPK-8011, a novel gene therapy for the treatment of hemophilia A, which is expected to start Phase 3 trials in 2019.

Roche Chief Executive Severin Schwan said the company planned to continue investing in Spark's portfolio.

Roche said Spark will continue to operate as an independent company within the Roche group.

Write to Anthony Shevlin at anthony.shevlin@dowjones.com

Stocks mentioned in the article
ChangeLast1st jan.
ROCHE HOLDING -0.68% 264.4 Delayed Quote.11.28%
ROCHE HOLDING LTD. -0.54% 264.65 Delayed Quote.9.35%
ROCHE HOLDING LTD. -0.17% 235.05 Delayed Quote.9.38%
SPARK THERAPEUTICS INC End-of-day quote.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING LTD.
05/15GENENTECH : 's Personalized Medicine Entrectinib Shrank Tumors Harboring NTRK, R..
BU
05/15Genentech Says FDA Approves Venclexta Plus Gazyva for Chronic Lymphocytic Leu..
DJ
05/15GENENTECH : Announces FDA Approval for Venclexta Plus Gazyva for People With Pre..
BU
05/14Roche Extends Offer Period for Spark Therapeutics
DJ
05/14SPARK THERAPEUTICS : Roche pushes back Spark takeover again as regulatory review..
RE
05/10GENENTECH : to Present New Data Highlighting Comprehensive Approach to Cancer Ca..
BU
05/08GENENTECH : to Present New OCREVUS (Ocrelizumab) Data Analyses Showing Significa..
BU
05/07GENENTECH : Presents Data from the Risdiplam Pivotal FIREFISH and SUNFISH Studie..
BU
05/06ROCHE : expands partnership with Bio-Techne to offer drug discovery researchers ..
PR
05/03Genentech Says FDA Approves Kadcyla for Treatment of Some Breast Cancer Patie..
DJ
More news
Financials (CHF)
Sales 2019 59 921 M
EBIT 2019 20 556 M
Net income 2019 13 860 M
Debt 2019 2 685 M
Yield 2019 3,40%
P/E ratio 2019 16,02
P/E ratio 2020 15,69
EV / Sales 2019 3,88x
EV / Sales 2020 3,67x
Capitalization 230 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 281  CHF
Spread / Average Target 5,4%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.9.38%227 259
JOHNSON & JOHNSON7.41%368 017
PFIZER-4.99%230 570
ROCHE HOLDING LTD.9.35%227 259
NOVARTIS13.20%210 489
MERCK AND COMPANY3.02%202 676